A Phase 2 Proof-of-Concept Trial to Evaluate an Investigational Gene Therapy FX201 in Patients with Knee Osteoarthritis (OA)
Latest Information Update: 22 Feb 2021
Price :
$35 *
At a glance
- Drugs Humantakinogene hadenovec (Primary)
- Indications Osteoarthritis
- Focus Proof of concept; Therapeutic Use
- Sponsors Flexion Therapeutics
- 22 Feb 2021 New trial record